



Rachmiel Levine-Arthur Riggs Diabetes Research Symposium

November 14-17; Pasadena, CA; Resource Hub – Draft

Welcome to our resource hub for Rachmiel Levine-Arthur Riggs Diabetes Research Symposium! This is a one-stop-shop for all your Rachmiel Arthur Levine-Riggs needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Table of Contents

[Useful Conference Links](#)

[Daily Coverage](#)

[Top Highlights](#)

[Previous Rachmiel Arthur Levine-Riggs Coverage on CCKB](#)

Useful Conference Links

1. [Conference Website](#)
2. [Conference Registration](#)
3. [Conference Program](#)
4. [Day-by-day Conference Preview](#)

Daily Coverage

1. [Day #1 Highlights](#)
2. [Day #2 Highlights](#)
3. [Day #3 Highlights](#)
4. [Day #4 Highlights](#)

Top Highlights

1. [Dr. Witkowski delivers an opening address](#) highlighting the evolution of islet transplantation treatments
2. [Tegoprubart as a less toxic alternative for immunosuppression](#) in islet allogenic transplantation
3. [Chemically induced pluripotent stem cell-derived islet transplantation](#) as the future of T1D cures
4. [Dr. Michael Rickels on stem cell-derived islets](#) and Vertex's VX-880 (zimiscelecel)
5. [Dr. Carmella Evans-Molina's "Christmas Wish List"](#) for the future of T1D research
6. [Rachmiel Levine Award Lecture](#): Yale's Dr. Kevan Herold on Tzield and T1D cures without systemic immunosuppression
7. [Circulating extracellular vesicles as potential mediators](#) (and therapeutic targets) for early β -cell injury in T1D
8. [RNA splicing as an overlooked mechanism of \$\beta\$ -cell failure](#)
9. [Immune intolerance in T1D](#) as a defect in the functional balance between T cell subtypes
10. [Using CAR T_{reg} cells to prevent islet transplantation rejection](#) in T1D
11. [Modifying the donor, rather than the recipient](#): Islet xenotransplantation as a potential cure for T1D

12. [Extraislet beta cells loss in T1D](#) highlights importance of early screening and intervention
13. [Quantifying individual T1D risk and response to disease-modifying therapies](#): Risk prediction model options and the quantitative response metric
14. [Prof. Anette-Gabriele Ziegler shares results and insights from the POInT](#) oral insulin T1D primary prevention trial
15. [Arthur Riggs Award Lecture](#): Dr. Alvin Powers on diabetes heterogeneity and advances in islet research
16. [The evolution of insulins](#): What's coming next to mimic beta cell activity?

Previous Rachmiel Arthur Levine-Riggs Coverage on CCKB

1. [2024 Resource Hub](#)
2. [2022 Full Report](#)
3. [2019 Full Report](#)
4. [2018 Full Report](#)
5. [2017 Full Report](#)
6. [2016 Full Report](#)
7. [2015 Full Report](#)
8. 2014 ([Day #1](#), [Day #2](#), [Day #3](#), and [Day #4](#))
9. [2013 Full Report](#)
10. [2012 Full Report](#).